Section Arrow
SPRB.NASDAQ
- Spruce Biosciences
(Financial Status)
Quotes are at least 15-min delayed:2025/04/12 04:14 EDT
Last
 0.291
-0.0041 (-1.39%)
Day High 
0.3115 
Prev. Close
0.2951 
1-M High
0.358 
Volume 
435.47K 
Bid
0.291
Ask
0.3198
Day Low
0.2685 
Open
0.2862 
1-M Low
0.257 
Market Cap 
12.19M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.29 
20-SMA 0.31 
50-SMA 0.35 
52-W High 0.87 
52-W Low 0.257 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.95/-0.61
Enterprise Value
14.92M
Balance Sheet
Book Value Per Share
1.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.09M
Operating Revenue Per Share
0.10
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed:2025/04/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.